Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial


ROCKVILLE, Md., Sept. 27, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that Eva Feldman, MD, PhD, Principal Investigator of the Phase I safety trial of Neuralstem's human spinal cord stem cells (HSSC's) in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), presented primary and secondary endpoint data on the first 12 patients at the American Neurological Association's annual meeting (http://www.aneuroa.org/i4a/pages/index.cfm?pageID=3311). Dr. Feldman, an unpaid consultant to Neuralstem, is also Director of the A. Alfred Taubman Medical Research Institute, the Director of Research of the ALS Clinic at the University of Michigan Health System and the incoming American Neurological Association President.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"Eight out of ten living subjects in the trial showed lower extremity function scores that remained the same or improved after treatment," commented. Dr. Feldman. "Two out of ten showed continued decline of lower extremity function. The sample size and follow-up time are too limited to draw any conclusions, but we are encouraged by the safety profile of our approach."


"This trial is designed to assess the safety of intraspinal transplantation in ALS. It is not an efficacy trial," said Karl Johe, PhD, Neuralstem Chairman and Chief Scientific Officer. "All assessments have proven the procedure to be safe. We have had no serious adverse events related to either the surgical procedure or our cells in the first 12 subjects. This is a very important first step to delivering the promise of our neural stem cell therapeutics."

more...

http://www.prnewswire.com/news-relea...130626513.html